Skip to main content
Caplight Logo









GluBio Therapeutics

GluBio Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://www.glubiotx.com/

Last Round

Strategic

Feb 11, 2026

Total Funding Raised

$122M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

GluBio Therapeutics is a biotechnology company that discovers and develops innovative molecular glue-targeted protein degradation drugs to address unmet medical needs in oncology, autoimmune diseases, and genetic disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

molecular glue degradersMGDstargeted protein degradationTPDdrug discovery platformAI drug discoverysmall-molecule therapeuticsundruggable proteinsrational drug designbiotech R&Dclinical-stage biotechcomputational biologyin silico drug designprotein degraderpharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GluBio Therapeutics Comparables

Compare GluBio Therapeutics with similar companies based on industry and business-model similarity.

GluBio Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Plexium
88%
SEED Therapeutics
84%
Neomorph
84%

GluBio Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicFeb 11, 2026
Series A ExtensionAug 1, 2022
Series AFeb 28, 2022
SeedFeb 1, 2021

Key People

Founding team and executive leadership

Liqiang Fu

Co-Founder & CTO

Founding Team

Gang Lu

Founder, President & CEO

Founding Team

GluBio Therapeutics Investors

Notable investors and investment history

GluBio Therapeutics investors
InvestorRounds
Hillhouse InvestmentSeries A
Kaitai CapitalSeries A, Series A Extension, Seed
Legend CapitalSeries A
E Fund ManagementSeries A
险峰K2VCSeries A, Seed
Lilly Asia VenturesSeries A, Series A Extension
Qiming Venture PartnersSeries A, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 56% MoM.

  • Jan 19, 2026

    Monthly visitors grew 1574% MoM, from 23 to 385.

GluBio Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GluBio Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GluBio Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range12
Year Founded2021
Last FundingFeb 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?